REG - Oxford Instruments - Trading Update

Oxford InstrumentsAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260115:nRSO9371Oa&default-theme=true

RNS Number : 9371O  Oxford Instruments PLC  15 January 2026

Oxford Instruments plc

Interim trading update - 15 January 2026

 

Group remains on track to meet full-year market expectations

Continued strong order momentum in Advanced Technologies

 

Oxford Instruments plc, ("Oxford Instruments" or "the Group"), a leading
provider of scientific technology tools and expertise to academic and
commercial partners, is today issuing a trading update for the three months
ended 31 December 2025 for continuing operations(1).

 

Trading update

 

The Group today reconfirms its full-year outlook, with reported adjusted
operating profit(2) anticipated to be in line with market expectations(3).

Order intake for the Imaging and Analysis (I&A) division showed continued
progress over Q2 and grew +2.4% OCC(4) versus Q3 last year. The year-to-date
book-to-bill ratio for the division is 1.1.  Cost restructuring actions
completed during H1 in our Belfast-based imaging business are delivering the
expected benefits in H2.

The third quarter has seen continued strong order momentum for the Advanced
Technologies (AT) division, with year-to-date orders up +44.5% OCC on the
prior year. Order book coverage now extends well into FY27.

The year-to-date book-to-bill ratio for the Group is 1.2.  The Group
continues to both book and ship new I&A orders within the fourth quarter,
with the main focus being on executing on the current orderbook across both
divisions.

NanoScience divestment

The sale of the NanoScience business completed on 2 January 2026. Net cash
proceeds from the sale were £48.5m, after the application of final closing
adjustments relating to working capital, and other debt-like items.

Defined benefit pension

On 5 December 2025 the Trustee of the Oxford Instruments Pension Scheme
purchased a policy with Royal London Mutual Insurance Society Limited ('Royal
London') to insure all members' Scheme benefits ('buy in').

As previously guided, pension contributions by the Company have ceased from
October 2025, with contributions expected to be £5.25m for the full year
FY26, and nil in all subsequent years.

Share buyback programme

As at 31 December 2025 £41.2m of the first £50m tranche of the share buyback
programme had been completed. The second £50m tranche of the programme will
follow on immediately upon completion of the first.

Currency

There is no change to guidance for the current financial year, with the
adjusted operating profit headwind for FY26 still expected to be c. £5.5m
versus the prior year.

Dates for Q4 trading update and FY 26 results

Oxford Instruments will issue a trading update on 14 April for the fourth
quarter and full year to 31 March 2026. Preliminary FY26 results will be
announced on 9 June 2026.

Notes:

1.         Excludes the NanoScience business and directly related
costs which exited the Group upon final deal closing.

2.         Adjusted items exclude the amortisation and impairment of
acquired intangible assets, acquisition items, business reorganisation costs,
other significant non‑recurring items, and the mark-to-market movement of
financial derivatives.

3.         Consensus for FY26 reported adjusted operating profit
ranges from £70.2m to £73.0m, with a mean of £71.8m.

4.         Organic constant currency numbers are prepared on a
month-by-month basis using the translational and transactional exchange rates
which prevailed in the previous year rather than the actual exchange rates
which prevailed in the year. Transactional exchange rates include the effect
of our hedging programme. They also exclude the impact of acquisitions and
divestment made in the comparator periods.

The financial information in this trading update is unaudited.

LEI: 213800J364EZD6UCE231

Enquiries:

Oxford Instruments plc

Richard Tyson, Chief Executive Officer

Paul Fry, Chief Financial Officer

Stephen Lamacraft, Director of Investor
Relations                                07776
433916

 
                     Stephen.lamacraft@oxinst.com

 

MHP Group

Katie Hunt/Tim
Rowntree/
                07710 117517

Veronica Farah
 
       oxfordinstruments@mhpgroup.com
(mailto:oxfordinstruments@mhpgroup.com)
 

Notes to Editors

About Oxford Instruments plc

Oxford Instruments provides academic and commercial organisations worldwide
with market-leading scientific technology and expertise across its key market
segments: materials analysis, semiconductors, and healthcare & life
science. Innovation is the driving force behind Oxford Instruments' growth and
success, supporting its core purpose to accelerate the breakthroughs that
create a brighter future for our world. The vigorous search for new ways to
make our world greener, healthier and more productive is driving unprecedented
levels of R&D investment in new materials and techniques to support
productivity and decarbonisation worldwide, creating a significant opportunity
for Oxford Instruments to grow. Oxford Instruments holds a unique position to
anticipate global drivers and connect academic researchers with commercial
applications engineers, acting as a catalyst that powers real world progress.
Founded in 1959 as the first technology business to be spun out from Oxford
University, Oxford Instruments is now a global, FTSE250 company listed on the
London Stock Exchange (OXIG). For more information, visit www.oxinst.com
(http://www.oxinst.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTAKQBNABKDODD



            Copyright 2019 Regulatory News Service, all rights reserved